Current evidence sets the functional floor at 1·2 g per kilogram of total body weight per day during active GLP-1 cut phases. The 2025 AJCN joint advisory refines this to 1·5 g/kg of fat-free mass per day. Observed intake in GLP-1 users averages just 0·6 g/kg/day, directly explaining the 25–39% lean-mass fraction of total weight lost on semaglutide and tirzepatide.
How Far Below the Protective Threshold Do GLP-1 Users Actually Fall?
A 2026 observational study found that weight-adjusted protein intake among GLP-1 receptor agonist users averaged 0·6 g/kg/day, with 88% of participants falling below the minimum adequate threshold. This represents roughly half the intake required to sustain muscle protein balance during a caloric deficit, and it is a direct consequence of drug-driven appetite suppression compressing total food volume.
GLP-1 receptor agonists reduce total energy intake by 20–35% below habitual levels through central appetite suppression and peripheral gastric-emptying delay. When total caloric intake contracts, protein intake contracts proportionally unless it is actively defended. The majority of GLP-1 users do not actively defend it.
The AJCN 2025 joint advisory (Mozaffarian et al.) flagged this as the primary nutritional risk of GLP-1 therapy. Protein intake must not fall below 0·4–0·5 g/kg/day to avoid muscle atrophy and functional impairment. That floor was already being breached by 88% of users in the 2026 study.
What Proportion of Weight Lost Is Lean Mass on Semaglutide Versus Tirzepatide?
STEP-1 DXA substudy data show semaglutide 2·4 mg/week produced approximately 15% total body weight loss over 68 weeks, with 39–40% of that loss classified as lean mass, representing roughly 9·7% absolute lean mass reduction. Tirzepatide's SURMOUNT-1 DXA substudy (Look et al., 2025) reported a more favourable split: approximately 75% fat mass and 25% lean mass of total weight lost.
Semaglutide's 39% lean fraction is substantially worse than the 20–30% lean fraction typically observed with diet-and-exercise weight loss alone. Tirzepatide's 25% lean fraction approaches the diet-and-exercise benchmark, likely reflecting GIP receptor co-agonism effects on skeletal muscle metabolism.
Neither trial controlled for protein intake or resistance training. The lean-mass loss figures therefore represent outcomes under ad libitum dietary conditions, conditions in which the 0·6 g/kg/day observed intake deficit was almost certainly present. They represent a floor, not an optimised outcome.
What Are the Evidence-Based Protein Targets Across Different GLP-1 Cut-Phase Contexts?
Three reference points emerge from the 2024–2026 literature. The absolute floor is 1·2 g/kg total body weight per day, per the Diabetes, Obesity and Metabolism 2025 review. The precision target is 1·5 g/kg fat-free mass per day per the AJCN 2025 advisory. Resistance-trained individuals in aggressive deficits benefit from 1·6–2·2 g/kg total body weight per day.
The distinction between targets expressed per kilogram of total body weight versus fat-free mass matters numerically. A 100 kg individual with 40% body fat has 60 kg of fat-free mass. At 1·2 g/kg total body weight, the target is 120 g/day; at 1·5 g/kg FFM, it is 90 g/day.
The FFM-based target is more conservative for high-adiposity individuals, which describes most GLP-1 therapy candidates. The total-body-weight target is more conservative for leaner individuals. Practitioners should apply whichever reference basis yields the higher absolute gram target for each patient.
The Tinsley et al. (2025) PMC review reported that individuals who preserved or increased lean mass during GLP-1 treatment had typical protein intakes of 1·2–1·7 g/kg/day. Those with the greatest lean mass loss clustered at the lower end of the 0·7–1·2 g/kg/day range. This dose-response pattern aligns with leucine-threshold kinetics.
Why Is Per-Meal Protein Distribution a Separate Variable From Total Daily Intake?
Muscle protein synthesis is triggered per-meal, not per-day. A minimum of 2·5 g of leucine per eating occasion is required to activate mTORC1 at the lysosomal surface, equivalent to 25–30 g of high-quality protein in younger adults and 30–40 g in adults over 60. GLP-1-driven satiety compresses meal frequency and volume, making this per-meal threshold the binding constraint.
A 2024 review (Layman et al., PMC11099237) confirmed that even protein distribution across at least three to four daily eating occasions produces superior lean mass outcomes versus the same total intake consumed asymmetrically. GLP-1 users who consolidate eating into one or two large meals miss the anabolic window at skipped meals regardless of whether daily totals are adequate.
The practical implication is that protein-dense, low-volume foods become structurally necessary. Greek yoghurt, cottage cheese, egg whites, and whey protein isolate deliver 20–30 g of protein in 150–250 kcal. This allows the per-meal threshold to be met even when total meal volume is severely compressed by GLP-1-driven early satiety.
Do Tirzepatide Users Require a Different Protein Target Than Semaglutide Users?
No controlled trial has directly compared protein requirements between tirzepatide and semaglutide users. Mechanistically, tirzepatide's GIP receptor co-agonism may reduce the protein intake needed to achieve equivalent lean-mass protection by improving postprandial amino acid delivery to skeletal muscle microvasculature. The practical protein target remains the same 1·2–1·5 g/kg range until direct comparative data exist.
The SURMOUNT-1 DXA data showing tirzepatide's 75% fat / 25% lean split versus semaglutide's 60% fat / 39% lean split suggests tirzepatide users start from a better lean-mass baseline. This advantage was observed under ad libitum dietary conditions, the same low-protein environment documented in the 2026 observational study.
Structured protein targeting on tirzepatide may therefore produce proportionally greater lean-mass preservation than the same protocol on semaglutide. This hypothesis has not been tested prospectively and remains mechanistically inferred from the DXA substudy data.
Does Protein Source Quality Alter the Effective Target During a GLP-1 Cut Phase?
Yes: leucine density and digestibility-corrected amino acid score (DIAAS) determine how much total protein is needed to hit the per-meal leucine threshold. Whey protein and eggs deliver approximately 10–11% leucine by weight, reaching the 2·5 g leucine threshold at 23–25 g total protein. Most plant proteins deliver 6–8% leucine, requiring 31–42 g per meal for the same mTORC1 trigger.
This source-quality differential is clinically significant during GLP-1 therapy because meal volume is constrained. A user relying on plant protein sources who targets 1·2 g/kg total body weight per day may be functionally under-dosing the per-meal leucine signal at every eating occasion, even while meeting the total daily gram target.
The effective protein target for plant-dominant diets during GLP-1 cut phases is closer to 1·6–2·0 g/kg total body weight per day to compensate for lower leucine density. This adjustment has not been formally tested in GLP-1 users but follows directly from leucine-threshold data in adjacent populations.
How Does Anabolic Resistance in Older Adults Shift the Protein Target?
Adults over 60 exhibit anabolic resistance, a blunted muscle protein synthesis response to a given leucine dose, raising the per-meal threshold to 30–40 g and pushing the daily target toward 1·6–2·0 g/kg bodyweight. ENDO 2025 data (Haines et al.) identified older adults and women on semaglutide as disproportionately at risk, with higher protein intake showing the strongest protective signal.
Anabolic resistance in older adults reflects reduced mTORC1 sensitivity to leucine, lower basal muscle protein synthesis rates, and elevated basal muscle protein breakdown. GLP-1-driven caloric restriction compounds all three mechanisms simultaneously. The protein intake floor that protects lean mass in a 35-year-old is therefore insufficient for a 65-year-old on the same GLP-1 regimen.
Leucine supplementation, adding 2–3 g of free leucine to a meal that would otherwise fall below threshold, is a practical strategy for older adults who cannot achieve the required per-meal protein dose through whole food alone. This approach has been validated in anabolic resistance literature independent of GLP-1 therapy and is mechanistically applicable to this context.
Where Do the Open Research Questions Stand as of 2026?
No prospective RCT has randomised GLP-1 therapy users to structured protein targets with DEXA-measured lean mass as the primary endpoint. The NCT06885736 trial (LEAN Mass Preservation study) is actively recruiting to address this gap. Until its results are published, the current 1·2–1·5 g/kg targets remain extrapolated from adjacent populations rather than directly validated in GLP-1 users.
The comparative protein requirement between tirzepatide and semaglutide users has not been tested in a controlled design. The protein source composition question, whether plant-protein users require a higher total intake to achieve equivalent lean-mass protection, has not been examined in this population. Both are clinically relevant gaps given the diversity of dietary patterns among GLP-1 therapy candidates.
For the mechanistic basis of how leucine and mTORC1 interact during incretin therapy, see How Does High Protein Intake Work With Incretin Mimetics to Preserve Muscle Protein Synthesis During Deep Caloric Deficits in 2026? For the resistance-training component of lean-mass protection, see Does Resistance Training Fundamentally Change How GLP-1 Therapies Like Semaglutide Affect Lean Mass in 2026? For the clinical evidence on tirzepatide versus semaglutide body composition outcomes, see Does Tirzepatide Improve Body Composition and Eating Behavior More Than Semaglutide in Metabolic Treatment in 2026? Which GLP-1/GIP Combination Peptide Protocols Best Preserve Lean Mass While Improving Glycemic Control in 2026 Self-Experimentation? What Do 2026 Primary Studies Show About GLP-1/GIP Dual Agonists Versus GLP-1 Monotherapy for Body-Weight Loss and Cardiometabolic Outcomes? What Does 2026 Research Show About Tirzepatide's Clinical Efficacy and Safety in Metabolic Diseases Beyond Diabetes and Obesity?